Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases.
OBJECTIVE
To report to the literature the largest published series of epidemic Kaposi's sarcoma (EKS), treated with radiation therapy, to summarize and discuss our 10 years experience in the treatment of this malignancy.


METHODS
From June 1986 to December 1996, 643 patients with acquired immunodeficiency syndrome (AIDS)-related epidemic Kaposi's sarcoma were treated with radiation therapy (RT) at the Cancerology Department of Henri Mondor University Hospital. The patients, 640 men and 3 women had an average age of 38.5 years (range 20-68 years). Three hundred eighty-seven patients (60.1 %) had received previous treatment for their Kaposi's sarcoma (KS). In total, 6777 fields were irradiated, as follows: face 1342 (19.8%), eyelid and conjunctiva 362 (5.3%), trunk 1903 (28.1%), upper and lower limbs 2866 (42.3%), genitals 189 (2.8%). and oral cavity 115 fields (1.7%). Radiation therapy consisted of 4 MV or 45-70 kV X-rays, depending on tumor size and location. Doses ranged from 10 to 30 Gy, according to tumor response and toxicity.


RESULTS
Objective response (CR and PR) was observed in 92% (5947/6464) of all cases, treated for cutaneous form of EKS. All patients with irradiated oral lesions had an objective response. The overall tolerance was acceptable for the cutaneous lesions. By contrast, in oral lesions, mucosal reactions were often observed after relatively low doses of radiotherapy.


CONCLUSIONS
Doses of 15 Gy for oral lesions, 20 Gy for lesions involving eyelids, conjunctiva, and genitals, have been shown to be sufficient to produce shrinkage of the tumor and good palliation of the symptoms. For the cutaneous EKS, we propose 30 Gy given in a local field, using a fractionated scheme with small size applicators. Radiotherapy has its own place in the management of EKS, as an efficient treatment.
Kirova
Y M
YM
University Hospital Henri Mondor, Department of Cancerology, Creteil, France.
Belembaogo
E
E
Frikha
H
H
Haddad
E
E
Calitchi
E
E
Levy
E
E
Piedbois
P
P
Le Bourgeois
J P
JP
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000368:Aged; D003230:Conjunctival Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000532:radiotherapy; D004307:Dose-Response Relationship, Radiation; D005142:Eyelid Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000532:radiotherapy; D005260:Female; D005500:Follow-Up Studies; D005833:Genital Neoplasms, Female / Q000453:epidemiology / Q000209:etiology / Q000532:radiotherapy; D005834:Genital Neoplasms, Male / Q000453:epidemiology / Q000209:etiology / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000532:radiotherapy; D012008:Recurrence; D012189:Retrospective Studies; D012514:Sarcoma, Kaposi / Q000453:epidemiology / Q000209:etiology / Q000532:radiotherapy*; D012878:Skin Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000532:radiotherapy; D016896:Treatment Outcome